Stockscreener 앱 받기
3.80
9.52%
-0.40
시간 외 거래:
3.88
0.08
+2.11%
전일 마감가:
$4.20
열려 있는:
$4.18
하루 거래량:
2.01M
Relative Volume:
0.89
시가총액:
$460.13M
수익:
$7.83M
순이익/손실:
$-64.92M
주가수익비율:
-7.1739
EPS:
-0.5297
순현금흐름:
$-47.22M
1주 성능:
+8.88%
1개월 성능:
+24.18%
6개월 성능:
+100.00%
1년 성능:
+171.43%
1일 변동 폭
$3.79
$4.19
1주일 범위
$3.52
$4.22
52주 변동 폭
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.80 | 508.57M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - marketbeat.com
Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat
Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - marketbeat.com
Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving AverageShould You Sell? - marketbeat.com
ACRS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Analyst Upgrade: Why is Aclaris Therapeutics Inc stock going upMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Wrap: Why is Aclaris Therapeutics Inc stock going up2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart
Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life - Quiver Quantitative
Experimental eczema pill cut disease severity 77% in 12-week trial - Stock Titan
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting - MyChesCo
Vanguard (ACRS) Amends Schedule 13G; Reports 0 Shares After Realignment - Stock Titan
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Published on: 2026-03-26 16:32:45 - baoquankhu1.vn
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis - MyChesCo
Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst - MarketBeat
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Published on: 2026-03-22 04:18:49 - baoquankhu1.vn
Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data - Investing.com
Deep Track Capital, LP Acquires Significant Stake in Aclaris Therapeutics Inc - GuruFocus
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The Manila Times
Aclaris Therapeutics Announces ePoster Presentation on Phase 2a Trial Results of ATI-2138 for Moderate-to-Severe Atopic Dermatitis at AAD Annual Meeting 2026 - Quiver Quantitative
Aclaris Therapeutics Announces Poster on Results from Phase - GlobeNewswire
Aclaris stock maintained at Buy by H.C. Wainwright on trial progress - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
Aclaris completes enrollment in atopic dermatitis trial By Investing.com - Investing.com Canada
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings - MarketBeat
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bitget
Aclaris Therapeutics completes enrollment in phase 2 trial of bosakitug (ATI-045) in atopic dermatitis - marketscreener.com
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis - TradingView
Aclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026 - quiverquant.com
109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan
Deep Track entities hold 9.35M Aclaris shares (ACRS) — 7.01% stake - Stock Titan
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Aclaris Therapeutics Raises $20 Million in Equity Financing - The Globe and Mail
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.11%
자본화:
|
볼륨(24시간):